Commit Biologics

Commit Biologics is developing the Bispecific Complement Engaging (BiCE) platform, a novel approach to activate the complement system for treating cancer and autoimmune diseases. The platform uses single domain antibodies to target and kill specific cells, leveraging the body's natural immune response. This modular system offers a highly targeted and effective method for therapeutic intervention.

Buy Funded Startups lists

Funding Round: Seed

Funding Amount: €21.5m

Date: 28-Jan-2025

Investors: Korys, Novo Holdings, Bioqube Ventures

Markets: Biotechnology, Pharmaceuticals, Immunotherapy, Life Science, Medical, Therapeutics

HQ: Aarhus, Middle Jutland, Denmark

Founded: 2021

Website: https://commitbio.com/

LinkedIn: https://www.linkedin.com/company/commit-biologics

Twitter:

Instagram: